

Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, Discovery Sciences, **AstraZeneca**

Dr. Beverley Isherwood, Ph.D. is the group lead for High Content Biology at AstraZeneca, with responsibility for phenotypic high-content assay and profiling activities across all AZ therapeutic areas, including Oncology, Cardiovascular and Metabolic Disease and Respiratory and Inflammation. Her accountabilities include managing the development and application of phenotypic assays across the value chain, implementing new technologies and approaches for phenotypic-led drug discovery and overseeing a state-of-the art centralised open-access cell sciences laboratory based at AstraZeneca UK. Prior to this, Dr. Isherwood held Senior Scientist and Team Leader positions within the Advanced Science and Technology Laboratory at AstraZeneca, where she focused on the implementation of novel technologies to improve the productivity and predictivity of drug discovery. Before joining AstraZeneca in 2006, Dr. Isherwood held a postdoctoral research position at Pfizer where her work focused on the identification of novel targets for antiviral therapeutics. Dr. Isherwood holds a PhD in Molecular Virology from the MRC Virology Unit, Glasgow University and an MA (Natural Sciences) from the University of Cambridge.